The stock price of Immuneering Corp (NASDAQ: IMRX) has dropped by -7.55 compared to previous close of 2.12. Despite this, the company has seen a fall of -4.39% in its stock price over the last five trading days. globenewswire.com reported 2025-05-29 that CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 4-5, 2025, to discuss the company’s pipeline, platform, and business strategy.
Is It Worth Investing in Immuneering Corp (NASDAQ: IMRX) Right Now?
The stock has a 36-month beta value of 0.03. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IMRX is 25.96M, and at present, short sellers hold a 3.56% of that float. On June 13, 2025, the average trading volume of IMRX was 214.91K shares.
IMRX’s Market Performance
IMRX’s stock has seen a -4.39% decrease for the week, with a 53.13% rise in the past month and a 27.27% gain in the past quarter. The volatility ratio for the week is 4.21%, and the volatility levels for the past 30 days are at 5.24% for Immuneering Corp The simple moving average for the past 20 days is 10.36% for IMRX’s stock, with a 7.19% simple moving average for the past 200 days.
Analysts’ Opinion of IMRX
Needham, on the other hand, stated in their research note that they expect to see IMRX reach a price target of $15, previously predicting the price at $20. The rating they have provided for IMRX stocks is “Buy” according to the report published on March 15th, 2024.
IMRX Trading at 30.93% from the 50-Day Moving Average
After a stumble in the market that brought IMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.83% of loss for the given period.
Stock Fundamentals for IMRX
The total capital return value is set at -1.41. Equity return is now at value -102.48, with -89.10 for asset returns.
Based on Immuneering Corp (IMRX), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -13.13.
Currently, EBITDA for the company is -63.69 million with net debt to EBITDA at 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.48.
Conclusion
To sum up, Immuneering Corp (IMRX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
